(+)-沙利度胺
(+)-沙利度胺 性质
| 熔点 | 269-271°C |
|---|---|
| 沸点 | 401.48°C (rough estimate) |
| 密度 | 1.2944 (rough estimate) |
| 折射率 | 1.5300 (estimate) |
| 储存条件 | -20°C Freezer |
| 溶解度 | 可溶于DMSO |
| 形态 | 固体 |
| 酸度系数(pKa) | 10.70±0.40(Predicted) |
| 颜色 | 白色 |
| InChI | 1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m1/s1 |
| InChIKey | UEJJHQNACJXSKW-SECBINFHSA-N |
| SMILES | O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1 |
(+)-沙利度胺 用途与合成方法
The transport of the (R)-Thalidomide from the R-imprinted MIP-1 through the donor phase to the receiver phase is much less owing to the stronger retention of the thalidomide in the organic phase. With the affinity of (R)-Thalidomide by the MIP present surface capture, that is more strongly than the other forms. In the case of (R)-Thalidomide, it is found to bind to the selective sites of the MIP more strongly than the other which reflects their different biological entities.
The (S)-Thalidomide imprints MIP nanoparticles exerted a greater cytotoxic effect on the caco-2 cells than the (R)-Thalidomide imprinted MIPs.
Adult female F344 rats are implanted with 9L gliosarcoma tumours intracranially, subcutaneously (flank), or both. Effectiveness of oral thalidomide alone, and with intraperitoneal BCNU or cisplatin combination chemotherapy, is assessed after several weeks treatment. Both serum and tissue concentrations of (R)-thalidomide are 40-50% greater than those of (S)-thalidomide. Co-administration of BCNU or cisplatin with thalidomide did not alter the concentration enantioselectivity.
安全信息
| 危险品标志 | T |
|---|---|
| 危险类别码 | 61-22 |
| 安全说明 | 53-36/37/39-45 |
| WGK Germany | 3 |
| RTECS号 | TI4925000 |
| 存储类别 | 6.1C - 可燃，急性毒性 类别3 毒性化合物或者引起慢性影响的化合物 |
| 危险性类别 | 急性毒性 类别4 经口 生殖毒性 类别1B |
(+)-沙利度胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-14658B | (+)-沙利度胺 | 2614-06-4 | 1 mg | 640 |
| 2026-09-15 | HY-14658B | (+)-沙利度胺 | 2614-06-4 | 5 mg | 1440 |
